Osteoporosis Fracture Clinical Trial
Official title:
Evaluation of the Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration Following Severe Osteoporotic Fracture in Patients Aged 75 and Over, Hospitalized at the Rocheplane Medical Center
The aim of this observational study is to assess the obstacles and levers to the continuation of anti-osteoporotic treatment, and to identify those where action could be taken to improve the quality of care for fractured patients. The individual and collective stakes are high. Fracture is the most feared complication of osteoporosis. The current under-diagnosis and under-treatment of this chronic pathology exposes patients to a high risk of early re-fracture, with the associated morbidity and mortality. General practitioners have a major role to play in monitoring and coordinating patients' healthcare pathways. The aim of this study is to assess ways of improving osteoporosis management in order to improve quality of life and disability-free life expectancy for individual patients. The public health and economic stakes are equally high. It is by identifying the obstacles that prospective work on the key elements to be implemented could help optimize osteoporosis management.
Selection of patients hospitalized at the Rocheplane Medical Center between June 2021 and May 2022, following a severe osteoporotic fracture and having received a first dose of antiosteoporotic treatment during their overall stay (initial admission department + CMR). Sending of an information letter and request for non-objection from patients or their trusted support person, with a 1-month cooling-off period to express opposition. Collection of variables of interest from CMR patients' medical records, followed by administration of a telephone hetero-questionnaire (transferred to Excel) to patients or their families 1 year after fracture occurrence. If the patient or family did not answer the questionnaire, or if it was incomplete (missing data), the information could be sought by telephone from the attending physician. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
| Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
| Completed |
NCT03798444 -
Height Loss, Kyphosis Indicators, Bone Mineral Density and Vertebral Fractures in Chinese Postmenopausal Women
|
||
| Completed |
NCT04960033 -
Evaluating Fracture Risk Assessment Tools (FRAX) From Different Regions in Central South Chinese Postmenopausal Women
|
||
| Not yet recruiting |
NCT04597931 -
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
|
Phase 4 | |
| Completed |
NCT05366621 -
Post-fracture Medication and Mortality
|
||
| Completed |
NCT02483286 -
Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area
|
N/A | |
| Enrolling by invitation |
NCT03178799 -
Randomized Fracture Liaison Services
|
||
| Completed |
NCT02803190 -
Osteoporosis and Fall Prevention and Posture Correction Interventions in the Metropolitan Area
|
N/A | |
| Recruiting |
NCT03451305 -
Postrual Reduction With Pillow in Osteoporotic Vertebral Fracture
|
N/A | |
| Recruiting |
NCT03811509 -
Breast Cancer Women on Aromatase Inhibitors Treatment
|
Phase 4 | |
| Recruiting |
NCT06379243 -
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
|
N/A |